Top

Published in:

14-10-2023 | Parkinson's Disease | Editorial

Tackling the usefulness of neurofilament light chain in multiple system atrophy: diagnostic and prognostic perspectives

Authors: Daniel G. Di Luca, Patricio Millar Vernetti

Published in: Clinical Autonomic Research | Issue 6/2023

Excerpt

Multiple system atrophy (MSA) is a rapidly progressive fatal neurodegenerative disease characterized by parkinsonism and/or cerebellar ataxia accompanied by cardiovascular and urogenital autonomic dysfunction, with no available disease-modifying treatments to date [1]. Among the many challenges in the field, obtaining a reliable biomarker for diagnostic and prognostic purposes remains a challenge. This also leads to significant difficulty in objectively characterizing disease progression in MSA, and potentially evaluating treatment response for prospective disease-modifying therapies. Several biomarkers have been explored in the recent past, with neurofilament light chain (NfL) being a potential candidate due to its association with rapid disease progression or a significant amount of neuronal injury. As a marker of axonal degeneration, both plasma and cerebral spinal fluid (CSF) concentrations of NfL have been described as potentially useful in distinguishing MSA from other parkinsonian syndromes, such as Parkinson’s disease (PD). Additionally, a large multicenter European study by Chelban et al. demonstrated that plasma NfL (NfL-p) could be useful in tracking MSA progression, and correlated with survival [2]. …

Poewe W et al (2022) Multiple system atrophy. Nat Rev Dis Primers 8(1):56. https://doi.org/10.1038/s41572-022-00382-6CrossRefPubMed

Chelban V et al (2022) Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145(12):4398–4408. https://doi.org/10.1093/brain/awac253CrossRefPubMedPubMedCentral

Singer W et al (2023) Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study. Clin Auton Res. https://doi.org/10.1007/s10286-023-00974-6CrossRefPubMed

Hall S et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol 69(11):1445. https://doi.org/10.1001/archneurol.2012.1654CrossRefPubMed

Hansson O et al (2017) Blood-based NfL. Neurology 88(10):930–937. https://doi.org/10.1212/WNL.0000000000003680CrossRefPubMedPubMedCentral

Wenning GK et al (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord. https://doi.org/10.1002/mds.29005CrossRefPubMedPubMedCentral

Singer W et al (2021) Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89(6):1212–1220. https://doi.org/10.1002/ana.26089CrossRefPubMedPubMedCentral

Zhang X et al (2023) Neurofilament light protein predicts disease progression in idiopathic rem sleep behavior disorder. J Parkinsons Dis 13(4):485–499. https://doi.org/10.3233/JPD-223519CrossRefPubMedPubMedCentral

Compta Y et al (2022) Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again. Parkinsonism Relat Disord 99:33–41. https://doi.org/10.1016/j.parkreldis.2022.05.006CrossRefPubMed

10.

Rojas JC et al (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90(4):e273–e281. https://doi.org/10.1212/WNL.0000000000004859CrossRefPubMedPubMedCentral

11.

Barba L et al (2023) CSF synaptic biomarkers in AT(N)-based subgroups of lewy body disease. Neurology 101(1):e50–e62. https://doi.org/10.1212/WNL.0000000000207371CrossRefPubMed

12.

Diekämper E et al (2021) Neurofilament levels are reflecting the loss of presynaptic dopamine receptors in movement disorders. Front Neurosci. https://doi.org/10.3389/fnins.2021.690013CrossRefPubMedPubMedCentral

13.

Miki Y et al (2019) Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 142(9):2813–2827. https://doi.org/10.1093/brain/awz189CrossRefPubMed

14.

Koga S et al (2015) When DLB, PD, and PSP masquerade as MSA. Neurology 85(5):404–412. https://doi.org/10.1212/WNL.0000000000001807CrossRefPubMedPubMedCentral

15.

Okuzumi A et al (2023) Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29(6):1448–1455. https://doi.org/10.1038/s41591-023-02358-9CrossRefPubMedPubMedCentral

Title: Tackling the usefulness of neurofilament light chain in multiple system atrophy: diagnostic and prognostic perspectives
Authors: Daniel G. Di Luca
Patricio Millar Vernetti
Publication date: 14-10-2023
Publisher: Springer Berlin Heidelberg
Keywords: Parkinson's Disease
Biomarkers
Progressive Supranuclear Palsy
Published in: Clinical Autonomic Research / Issue 6/2023
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-023-00992-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tackling the usefulness of neurofilament light chain in multiple system atrophy: diagnostic and prognostic perspectives

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2023

Engaging patients in the management of orthostatic intolerance

Sex differences in Black Veterans with PTSD: women versus men have higher sympathetic activity, inflammation, and blunted cardiovagal baroreflex sensitivity

Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure

The effects of oral contraceptives on resting autonomic function and the autonomic response to physiological stressors: a systematic review

Sweat gland nerve fiber density and association with sudomotor function, symptoms, and risk factors in adolescents with type 1 diabetes

Serotonin reuptake inhibition for the prevention of vasovagal syncope: a systematic review and meta-analysis